M(L)M(L)R(L)V(L)NS vaccine

The M(L)M(L)R(L)V(L)NS vaccine is an investigational, quadrivalent biological product developed by GSK to provide immunity against measles, mumps, rubella, and varicella (chickenpox). It is a live-attenuated vaccine formulation being evaluated in Phase II clinical trials. The specific 'M(L)M(L)R(L)V(L)NS' designation refers to a formulation where the measles, mumps, rubella, and varicella-zoster virus components are all included at a 'low' (L) potency level. This vaccine is intended for subcutaneous administration as a second dose in children aged 4 to 6 years who have previously received primary vaccinations for these four diseases. The development goal is to optimize the potency of the individual viral components to ensure robust immunogenicity and a favorable safety profile compared to existing licensed vaccines like ProQuad.

Other names

Investigational MMRVNS vaccineInvestigational measles, mumps, rubella, and varicella vaccine